“For far too long leaders have chosen the path of inaction, rather than action, and fallen victim to a pharmaceutical system driven by drug companies rather than consumers,” said Agency for Health Care Administration Secretary Simone Marstiller.
“Fortunately, Governor DeSantis leads with principle, always putting Floridians first and today’s actions will further this commitment by providing insight into the FDA’s review process and all agency health care contracts through the end of the decade.”
The Executive Order directs all executive agencies to include provisions in all future contracts and solicitations with these PBMs, services that include the following:
- Prohibit spread pricing for all PBMs;
- Prohibit reimbursement clawbacks for all PBMs;
- Directs agencies to include data transparency and reporting requirements, including a review of all rebates, payments, and relationships between pharmacies, insurers, and manufacturers; and
- Directs all impacted agencies to amend all contracts to the extent feasible with these same provisions.
A copy of Executive Order 22-164 can be found HERE.
Florida has taken previous actions to lower the costs of prescription drugs for residents that continue to be stalled by the federal government. The state’s landmark Canadian Prescription Drug Importation program has been under review by the FDA for nearly 600 days.
Governor DeSantis also announced today that the Agency for Health Care Administration (AHCA) filed a Freedom of Information Act (FOIA) request to gain insight into the status of their proposal to lower drug costs for Floridians.
The FDA must provide transparency on their review process, and Florida will hold them accountable to ensure they are not putting politics over patients.
In response to federal government inaction, Governor DeSantis granted AHCA authority to negotiate prices for drugs ineligible for importation, such as insulin and epinephrine. This will reinforce the demand for Florida’s Canadian Prescription Drug Importation Program and provide another avenue to impact the price Floridians pay for prescription drugs.